PPARG and metabolic dysfunction-associated steatotic liver disease: While PPARγ activation has been proposed as a therapeutic strategy for MASLD due to its ability to promote adipocyte differentiation and improve insulin sensitivity (Qiu et al., 2023), its role in MASLD remains complex and controversial.